TY - JOUR
T1 - Impact of the Opioid Epidemic on Drug Testing
AU - McMillin, Gwendolyn A.
AU - Johnson-Davis, Kamisha L.
AU - Kelly, Brian N.
AU - Scott, Bonnie
AU - Yang, Yifei K.
N1 - Publisher Copyright:
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2021/2/1
Y1 - 2021/2/1
N2 - BACKGROUND: This review provides a description of how the opioid epidemic has impacted drug testing. METHODS: Four major service areas of drug testing were considered, including emergency response, routine clinical care, routine forensics, and death investigations. RESULTS: Several factors that the opioid epidemic has impacted in drug testing are discussed, including specimens, breadth of compounds recommended for testing, time to result required for specific applications, analytical approaches, interpretive support requirements, and examples of published practice guidelines. CONCLUSIONS: Both clinical and forensic laboratories have adapted practices and developed new testing approaches to respond to the opioid epidemic. Such changes are likely to continue evolving in parallel with changes in both prescription and nonprescription opioid availability and use patterns, as well as emerging populations that are affected by the "waves" of the opioid epidemic.
AB - BACKGROUND: This review provides a description of how the opioid epidemic has impacted drug testing. METHODS: Four major service areas of drug testing were considered, including emergency response, routine clinical care, routine forensics, and death investigations. RESULTS: Several factors that the opioid epidemic has impacted in drug testing are discussed, including specimens, breadth of compounds recommended for testing, time to result required for specific applications, analytical approaches, interpretive support requirements, and examples of published practice guidelines. CONCLUSIONS: Both clinical and forensic laboratories have adapted practices and developed new testing approaches to respond to the opioid epidemic. Such changes are likely to continue evolving in parallel with changes in both prescription and nonprescription opioid availability and use patterns, as well as emerging populations that are affected by the "waves" of the opioid epidemic.
UR - http://www.scopus.com/inward/record.url?scp=85100069955&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100069955&partnerID=8YFLogxK
U2 - 10.1097/FTD.0000000000000841
DO - 10.1097/FTD.0000000000000841
M3 - Review article
C2 - 33230043
AN - SCOPUS:85100069955
SN - 0163-4356
VL - 43
SP - 14
EP - 24
JO - Therapeutic Drug Monitoring
JF - Therapeutic Drug Monitoring
IS - 1
ER -